OralParenteralDosed ingredientTherapeutic flag
Cosmetic cross-reference
Itraconazole
CAS 84625-61-6
Itraconazole (CAS 84625-61-6) is a Phase 4 pharmaceutical compound with 12 bioactivity targets and 1,200 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
24
SOURCE
DrugCentral
Adverse signals
1,200
SOURCE
IUPHAR/BPS
PubMed IDs
1
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Itraconazole
CAS Number
84625-61-6
UNII
304NUG5GF4
InChIKey
VHVPQPYKVGDNFY-UHFFFAOYSA-N
ChEMBL ID
CHEMBL64391
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Sporanox
black box warningdosed ingredientnatural productoralparenteraltherapeutic flag
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL64391 | Small molecule
SOURCE
Ingredients table / CosIng profile
same-CAS cross-reference
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
SOURCE
EMBL-EBI ChEMBL
24 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | MIC | 29.86641225626741 ug.mL-1 | 1075 | - |
| - | AC50 | 25541.302307692305 nM | 130 | - |
| - | IC50 | 8700.364285714286 nM | 95 | - |
| - | MIC | 7828.40396039604 nM | 94 | - |
| - | Potency | 7089.762222222222 nM | 40 | - |
| - | Kd | 1041.5714285714287 nM | 7 | - |
| - | Ki | 462.3333333333333 nM | 6 | - |
| - | EC50 | 22076.2 nM | 5 | - |
| - | IC50 | 16.687 ug.mL-1 | 3 | - |
| - | GI50 | 420 nM | 2 | - |
| - | MIC | 0.0664 | 2 | - |
| Beta-2 adrenergic receptor GPCR |
Ki | 6.3 | - | Homo sapiens |
| Cytochrome P450 3A4 Enzyme |
IC50 | 6.046 | - | Homo sapiens |
| ATP-binding cassette sub-family G member 2 Transporter |
IC50 | 5.7 | - | Homo sapiens |
| Lanosterol 14-alpha demethylase Enzyme |
MIC | 9.246 | - | Candida albicans (strain SC5314 / ATCC MYA-2876) |
| Vasopressin V2 receptor GPCR |
IC50 | 6.1 | - | Homo sapiens |
| Tyrosine-protein kinase Fyn Kinase |
IC50 | 5.41 | - | Homo sapiens |
| Lanosterol 14-alpha demethylase Enzyme |
IC50 | 5.44 | - | Homo sapiens |
| C-C chemokine receptor type 4 GPCR |
IC50 | 6.7 | - | Homo sapiens |
| C-X-C chemokine receptor type 1 GPCR |
IC50 | 7 | - | Homo sapiens |
| Cruzipain Enzyme |
IC50 | 5.52 | - | Trypanosoma cruzi |
| 14-alpha sterol demethylase Cyp51A Enzyme |
Kd | 6 | - | Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) |
| 14-alpha sterol demethylase Enzyme |
Kd | 7.51 | - | Neosartorya fumigata |
| 7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Enzyme |
IC50 | 5.33 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Drug interaction | 853 | 805.593 | 10013710 |
| Aspergillus infection | 153 | 318.11 | 10074171 |
| Bronchopulmonary aspergillosis | 131 | 238.737 | 10006473 |
| Febrile neutropenia | 351 | 235.165 | 10016288 |
| Drug resistance | 158 | 205.339 | 10059866 |
| Acute graft versus host disease | 92 | 190.676 | 10066260 |
| Hepatic function abnormal | 156 | 151.103 | 10019670 |
| Neutrophil count decreased | 176 | 148.948 | 10029366 |
| Symmetrical drug-related intertriginous and flexural exanthema | 38 | 148.297 | 10078325 |
| Pathogen resistance | 86 | 141.181 | 10034133 |
| Platelet count decreased | 249 | 127.798 | 10035528 |
| Drug level increased | 108 | 124.117 | 10013722 |
| Pain | 81 | 117.222 | 10033371 |
| Fungal infection | 113 | 115.693 | 10017533 |
| Hypokalaemia | 193 | 115.263 | 10021015 |
| Ileus paralytic | 60 | 114.797 | 10021333 |
| Acute graft versus host disease in skin | 57 | 113.533 | 10066262 |
| Cytomegalovirus test positive | 52 | 112.642 | 10051620 |
| Systemic mycosis | 41 | 111.501 | 10052366 |
| Cytomegalovirus infection | 105 | 105.536 | 10011831 |
| Myopathy | 74 | 104.809 | 10028641 |
| Pseudoaldosteronism | 21 | 102.771 | 10037113 |
| Cardiotoxicity | 65 | 98.154 | 10048610 |
| Histoplasmosis disseminated | 36 | 97.669 | 10020144 |
| Fatigue | 161 | 96.464 | 10016256 |
| Pseudohyponatraemia | 19 | 95.528 | 10072126 |
| Sepsis | 253 | 75.282 | 10040047 |
| Disseminated intravascular coagulation | 77 | 73.762 | 10013442 |
| Neutropenia | 262 | 72.873 | 10029354 |
| Parathyroid gland enlargement | 16 | 72.816 | 10051653 |
| Phaeohyphomycosis | 23 | 72.079 | 10080815 |
| Abdominal discomfort | 19 | 71.797 | 10000059 |
| Liver disorder | 112 | 71.471 | 10024670 |
| White blood cell count decreased | 194 | 70.595 | 10047942 |
| Renal impairment | 171 | 70.417 | 10062237 |
| Adrenal suppression | 25 | 70.356 | 10001382 |
| Adrenal insufficiency | 68 | 69.421 | 10001367 |
| Pyrexia | 459 | 66.221 | 10037660 |
| Lung transplant rejection | 24 | 65.829 | 10051604 |
| Rhabdomyolysis | 122 | 65.299 | 10039020 |
| Blood lactate dehydrogenase increased | 76 | 63.783 | 10005630 |
| Completed suicide | 3 | 63.369 | 10010144 |
| Rheumatoid arthritis | 11 | 63.298 | 10039073 |
| Pneumonia fungal | 44 | 62.734 | 10061354 |
| Immune reconstitution inflammatory syndrome | 46 | 62.581 | 10065042 |
| Upper respiratory fungal infection | 16 | 62.579 | 10062219 |
| Cytomegalovirus viraemia | 46 | 62.252 | 10058854 |
| Trichosporon infection | 20 | 61.571 | 10053461 |
| Acute myeloid leukaemia | 68 | 61.294 | 10000880 |
| Pseudomonas infection | 55 | 61.232 | 10061471 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
PharmGKB
1 phenotype row
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
CYP3A5 (PA131) CYP3A5*1, CYP3A5*3
CYP3A5 *1/*1 + *1/*3 are associated with decreased severity of inhibition of CYP3A-catalyzed metabolism of midazolam or testosterone when treated with itraconazole or ketoconazole in Human Liver Microsomes as compared to CYP3A5 *3/*3.
Evidence: -; PMID 23723360
SOURCE
NLM RxNorm
4 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| ITRACONAZOLE | 28031 | SU | MTHSPL |
| Itraconazole | 28031 | SU | MTHSPL |
| itraconazole | 28031 | IN | RXNORM |
| Sporanox | 202826 | BN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal bloating | itraconazole | LLT | C1291077 |
| Abdominal discomfort | itraconazole | PT | C0232487 |
| Abdominal distension | itraconazole | PT | C0000731 |
| Abdominal pain | itraconazole | LLT | C0000737 |
| Abdominal pain | itraconazole | PT | C0000737 |
| Abdominal pain upper | itraconazole | PT | C0232492 |
| Abnormal vision | itraconazole | LLT | C3665386 |
| Acute generalised exanthematous pustulosis | itraconazole | LLT | C0877055 |
| Acute generalised exanthematous pustulosis | itraconazole | PT | C0877055 |
| Acute hepatic failure | itraconazole | LLT | C0162557 |
| Acute hepatic failure | itraconazole | PT | C0162557 |
| Adrenal insufficiency | itraconazole | LLT | C0001623 |
| Adrenal insufficiency | itraconazole | PT | C0001623 |
| Agranulocytosis | itraconazole | LLT | C0001824 |
| Agranulocytosis | itraconazole | PT | C0001824 |
| Alanine aminotransferase increased | itraconazole | LLT | C0151905 |
| Alanine aminotransferase increased | itraconazole | PT | C0151905 |
| Albuminuria | itraconazole | LLT | C0001925 |
| Albuminuria | itraconazole | PT | C0001925 |
| Alopecia | itraconazole | LLT | C0002170 |
| Alopecia | itraconazole | PT | C0002170 |
| Anaphylactic shock | itraconazole | LLT | C0002792 |
| Anaphylactic shock | itraconazole | PT | C0002792 |
| Anaphylactic shock | itraconazole | PT | C0002792 |
| Anaphylactoid reaction | itraconazole | LLT | C0340865 |
| Anaphylactoid reaction | itraconazole | PT | C0340865 |
| Angioedema | itraconazole | LLT | C0002994 |
| Angioedema | itraconazole | PT | C0002994 |
| Angiopathy | itraconazole | LLT | C0042373 |
| Angiopathy | itraconazole | PT | C0042373 |
| Anorexia | itraconazole | LLT | C0003123 |
| Anxiety | itraconazole | LLT | C0003467 |
| Anxiety | itraconazole | PT | C0003467 |
| Application site reaction | itraconazole | LLT | C0151505 |
| Application site reaction | itraconazole | PT | C0151505 |
| Arrhythmia | itraconazole | LLT | C0003811 |
| Arrhythmia | itraconazole | PT | C0003811 |
| Arthralgia | itraconazole | LLT | C0003862 |
| Arthralgia | itraconazole | PT | C0003862 |
| Aspartate aminotransferase increased | itraconazole | LLT | C0151904 |
| Aspartate aminotransferase increased | itraconazole | PT | C0151904 |
| Asthenia | itraconazole | LLT | C0004093 |
| Asthenia | itraconazole | PT | C0004093 |
| Asthenia | itraconazole | PT | C0004093 |
| Back pain | itraconazole | LLT | C0004604 |
| Back pain | itraconazole | PT | C0004604 |
| Bacteriuria | itraconazole | LLT | C0004659 |
| Bacteriuria | itraconazole | PT | C0004659 |
| Bladder pain | itraconazole | PT | C0232849 |
| Blood alkaline phosphatase increased | itraconazole | PT | C0852911 |
| Blood alkaline phosphatase increased | itraconazole | LLT | C0852911 |
| Blood alkaline phosphatase increased | itraconazole | PT | C0852911 |
| Blood and lymphatic system disorders | itraconazole | - | C0851353 |
| Blood creatine phosphokinase increased | itraconazole | LLT | C0853034 |
| Blood creatine phosphokinase increased | itraconazole | PT | C0853034 |
| Blood creatinine increased | itraconazole | PT | C0235431 |
| Blood lactate dehydrogenase increased | itraconazole | PT | C0853149 |
| Blood lactate dehydrogenase increased | itraconazole | LLT | C0853149 |
| Blood lactate dehydrogenase increased | itraconazole | PT | C0853149 |
| Blood triglycerides increased | itraconazole | PT | C0853692 |
| Blood urea increased | itraconazole | LLT | C0151539 |
| Blood urea increased | itraconazole | PT | C0151539 |
| Body temperature increased | itraconazole | LLT | C0015967 |
| Body temperature increased | itraconazole | PT | C0015967 |
| Breast disorder | itraconazole | LLT | C0006145 |
| Breast disorder | itraconazole | PT | C0006145 |
| Breast pain | itraconazole | PT | C0024902 |
| Breast pain male | itraconazole | LLT | C0235792 |
| Bronchial hyperreactivity | itraconazole | PT | C0085129 |
| Bronchitis | itraconazole | LLT | C0006277 |
| Bronchitis | itraconazole | PT | C0006277 |
| Bronchospasm | itraconazole | LLT | C0006266 |
| Bronchospasm | itraconazole | PT | C0006266 |
| Bursitis | itraconazole | LLT | C0006444 |
| Bursitis | itraconazole | PT | C0006444 |
| Cardiac disorder | itraconazole | LLT | C0018799 |
| Cardiac disorder | itraconazole | PT | C0018799 |
| Cardiac failure | itraconazole | LLT | C0018801 |
| Cardiac failure | itraconazole | PT | C0018801 |
| Cardiac failure congestive | itraconazole | LLT | C0018802 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Itraconazole used for in pharmaceutical contexts?
Itraconazole (CAS 84625-61-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Itraconazole?
Itraconazole has 1,200 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Drug interaction, Aspergillus infection, Bronchopulmonary aspergillosis, Febrile neutropenia, Drug resistance. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Itraconazole also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Itraconazole with EU status "prohibited".
What clinical phase is Itraconazole in?
Itraconazole is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Itraconazole?
Itraconazole has 24 bioactivity rows in this page query. Rendered target entries include Beta-2 adrenergic receptor, Cytochrome P450 3A4, ATP-binding cassette sub-family G member 2, Lanosterol 14-alpha demethylase, Vasopressin V2 receptor.